Accuray Incorporated, developer and manufacturer of the CyberKnife® System, announced that published data from two multicenter studies using differing protocols provide consistent results and reinforce the use of the CyberKnife system for the effective management of low-and intermediate-risk prostate cancer.  The studies are the largest conducted to date evaluating stereotactic body radiation therapy (SBRT) in […]

Learn More

Watch general surgeon, Dr. Louis Heuser, talk about why he chose CyberKnife for the treatment of his prostate cancer. Dr. Heuser was very happy with the quick treatments and the fact that he was able to stay close to home and continue to work and see his patients. It’s Your Prostate, Your Cancer, Your Choice.

Learn More

Watch Douglas W. Widman, M.D., Medical Director at Columbus CyberKnife, and Thomas, a CyberKnife patient, talk about how CyberKnife is an excellent treatment option for prostate cancer. CyberKnife is as effective as surgery and is completed in only 5 outpatient treatment sessions compared to the 44 you have with traditional radiation therapy. In addition, CyberKnife […]

Learn More

Learn More

A recent article from CancerConnect.com, a patient-focused cancer website, suggests that if you have been diagnosed with cancer, seeking a second opinion will allow you to learn more about your cancer type and make truly informed decisions about treatment.  The article recommends that all cancer patients should consider seeing at least one additional expert after […]

Learn More

According to research presented at the recent 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO), high dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates.    Although prostate tumors generally respond well to radiation […]

Learn More